Tags : BouNDLess Trial

Mitsubishi Tanabe Reports Initiation of P-III BouNDLess Trial in Patients

Shots: The P-III BouNDLess study involves assessing of continuous carbidopa/levodopa (ND0612, SC) infusion vs immediate-release carbidopa/levodopa (CD/LD, PO) in 300 patients with PD experiencing motor fluctuations, evaluating its safety, efficacy and tolerability Mitsubishi’s subsidiary NeuroDerm is leading the P-III study with primary objective to determine the effect of ND0612 on daily “GOOD ON” time as […]Read More